About Raptor |
Raptor’s mission is to research, produce, and deliver medicines that improve life for patients with severe, rare diseases.
Raptor is a NASDAQ-listed biopharmaceutical company with a product pipeline that may advance therapeutic options for 8 different indications and includes potential for product launch within the next 18 months. Raptor's management team consists of repeat entrepreneurs with the experience to build a successful company.
The company has active development programs in cystinosis, a rare genetic disease, as well as other genetic and metabolic disorders.
Clinical Development Pipeline
Raptor is developing its proprietary delayed-release form of cysteamine (DR Cysteamine, or RP103 and RP104) for the potential treatment of:
- Nephropathic Cystinosis (Phase 3)
- Huntington’s Disease (Phase 2)
- Non-alcoholic Steatohepatitis (NASH) (Phase 2)
Additional clinical programs include:
Preclinical Pipeline
Raptor's preclinical pipeline includes novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein (RAP) and mesoderm development proteins (Mesd) to target cancer, neurodegenerative disorders and infectious diseases. These programs include:
Raptor's Receptor-Associated Protein (RAP) Platform
Raptor's Mesoderm Development Protein (Mesd) Product Candidate
